Spectranetics, FDA Discuss Laser Indication Approval After Panel Says No
This article was originally published in The Gray Sheet
Executive Summary
Spectranetics plans to use a 50-patient Belgium study to shore up support for an indication covering its CVX-300 excimer laser catheter system for critical limb ischemia patients with lesions not crossable with a guidewire
You may also be interested in...
FDA Passes On Critical Limb Ischemia Laser; Spectranetics Ponders Options
Spectranetics hopes FDA will accept a retrospective analysis of bypass surgery data as a control arm to support a critical limb ischemia indication for its CVX-300 excimer laser catheter system in lieu of further clinical studies
Spectranetics CVX-300 Panel Review Hindered By Historical Control Arm
FDA should have discouraged Spectranetics from conducting a non-randomized trial for critical limb ischemia (CLI), Circulatory System Devices Panel members asserted Oct. 2
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.